Multiple myeloma is a cancer of the plasma cells which are found in the bone marrow. In multiple myeloma, a group of monoclonal plasma cells (or myeloma cells) becomes cancerous and multiplies. These malignant plasma cells have the potential to affect many bones in the body, possibly resulting in compression fractures, lytic bone lesions and related pain. Multiple myeloma can cause a number of serious health problems affecting the bones, immune systems, kidneys and red blood cell count, with some of the more common symptoms including bone pain and fatigue, a symptom of anemia. Multiple myeloma is rare form of cancer, with approximately 114.000 new cases globally per year whereof approximately 800 per year in Belgium.
Takeda Oncology aspires to cure cancer by applying our commitment to science, to breakthrough innovation and to passion for improving patient care for people living with cancer around the world. Along with the global and local oncology communities, we make great strides in our fight against cancer. Our portfolio of paradigm-changing therapies combined with a dynamic, growing pipeline of investigational products have the potential to significantly improve patient outcomes across a number of types of cancer.